Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Intravitreous Pegaptanib Sodium Injection in patients with Exudative Age-Related Macular Degeneration (AMD)
This study is currently recruiting patients.
Sponsored by: | Eyetech Pharmaceuticals
Pfizer
|
---|---|
Information provided by: | Eyetech Pharmaceuticals |
Purpose
To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor’s other clinical studies with this drug for AMD, until such time as the patient’s lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available.
Condition | Treatment or Intervention |
---|---|
Macular Degeneration |
Drug: pegaptanib sodium |
MedlinePlus related topics: Macular Degeneration
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: An Open Label, Non-Comparative Protocol for use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients with Exudative Age-Related Macular Degeneration (AMD)
Study start: July 2004
Eligibility
Ages Eligible for Study: 50 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
General Criteria:
Exclusion Criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |